世界の二次高シュウ酸尿症薬市場インサイト及び予測(OTT薬、処方薬)

◆英語タイトル:Global Secondary Hyperoxaluria Drug Market Insights, Forecast to 2028

QYResearchが発行した調査報告書(QY22JLX09282)◆商品コード:QY22JLX09282
◆発行会社(リサーチ会社):QYResearch
◆発行日:2022年7月(※2025年版があります。お問い合わせください。)
◆ページ数:118
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥744,800見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,117,200見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,489,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、二次高シュウ酸尿症薬のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に二次高シュウ酸尿症薬の世界市場のxxx%を占める「OTT薬」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「病院薬局」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
二次高シュウ酸尿症薬の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパの二次高シュウ酸尿症薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

二次高シュウ酸尿症薬のグローバル主要企業には、Nestle、Glaxosmithkline Plc、Bayer Ag、Now Foods、Solgar Inc.、Pharmavite、Infinitus (china)、Mission Pharmacal Company、Oyster Shell、Allena Pharmaceuticals, Inc.、Amway Corp.、Celebrate Vitamins、Entring, Llc、Nature's Bounty、Oxthera、Renew Life Formulas, Inc.、Synlogic、Tiensなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

二次高シュウ酸尿症薬市場は、種類と用途によって区分されます。世界の二次高シュウ酸尿症薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
OTT薬、処方薬

【用途別セグメント】
病院薬局、オンライン薬局、小売薬局

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 二次高シュウ酸尿症薬製品概要
- 種類別市場(OTT薬、処方薬)
- 用途別市場(病院薬局、オンライン薬局、小売薬局)
- 調査の目的
・エグゼクティブサマリー
- 世界の二次高シュウ酸尿症薬販売量予測2017-2028
- 世界の二次高シュウ酸尿症薬売上予測2017-2028
- 二次高シュウ酸尿症薬の地域別販売量
- 二次高シュウ酸尿症薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別二次高シュウ酸尿症薬販売量
- 主要メーカー別二次高シュウ酸尿症薬売上
- 主要メーカー別二次高シュウ酸尿症薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(OTT薬、処方薬)
- 二次高シュウ酸尿症薬の種類別販売量
- 二次高シュウ酸尿症薬の種類別売上
- 二次高シュウ酸尿症薬の種類別価格
・用途別市場規模(病院薬局、オンライン薬局、小売薬局)
- 二次高シュウ酸尿症薬の用途別販売量
- 二次高シュウ酸尿症薬の用途別売上
- 二次高シュウ酸尿症薬の用途別価格
・北米市場
- 北米の二次高シュウ酸尿症薬市場規模(種類別、用途別)
- 主要国別の二次高シュウ酸尿症薬市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの二次高シュウ酸尿症薬市場規模(種類別、用途別)
- 主要国別の二次高シュウ酸尿症薬市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の二次高シュウ酸尿症薬市場規模(種類別、用途別)
- 主要国別の二次高シュウ酸尿症薬市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の二次高シュウ酸尿症薬市場規模(種類別、用途別)
- 主要国別の二次高シュウ酸尿症薬市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの二次高シュウ酸尿症薬市場規模(種類別、用途別)
- 主要国別の二次高シュウ酸尿症薬市場規模(トルコ、サウジアラビア)
・企業情報
Nestle、Glaxosmithkline Plc、Bayer Ag、Now Foods、Solgar Inc.、Pharmavite、Infinitus (china)、Mission Pharmacal Company、Oyster Shell、Allena Pharmaceuticals, Inc.、Amway Corp.、Celebrate Vitamins、Entring, Llc、Nature's Bounty、Oxthera、Renew Life Formulas, Inc.、Synlogic、Tiens
・産業チェーン及び販売チャネル分析
- 二次高シュウ酸尿症薬の産業チェーン分析
- 二次高シュウ酸尿症薬の原材料
- 二次高シュウ酸尿症薬の生産プロセス
- 二次高シュウ酸尿症薬の販売及びマーケティング
- 二次高シュウ酸尿症薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 二次高シュウ酸尿症薬の産業動向
- 二次高シュウ酸尿症薬のマーケットドライバー
- 二次高シュウ酸尿症薬の課題
- 二次高シュウ酸尿症薬の阻害要因
・主な調査結果

Market Analysis and Insights: Global Secondary Hyperoxaluria Drug Market
The global Secondary Hyperoxaluria Drug market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, OTT Medicine accounting for % of the Secondary Hyperoxaluria Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals Pharmacy segment is altered to an % CAGR throughout this forecast period.
China Secondary Hyperoxaluria Drug market size is valued at US$ million in 2021, while the North America and Europe Secondary Hyperoxaluria Drug are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Secondary Hyperoxaluria Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Secondary Hyperoxaluria Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Secondary Hyperoxaluria Drug market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Secondary Hyperoxaluria Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Secondary Hyperoxaluria Drug market.
Global Secondary Hyperoxaluria Drug Scope and Market Size
Secondary Hyperoxaluria Drug market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Secondary Hyperoxaluria Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
OTT Medicine
Prescription Medicine
Segment by Application
Hospitals Pharmacy
Online Pharmacy
Retail Pharmacy
By Company
Nestle
Glaxosmithkline Plc
Bayer Ag
Now Foods
Solgar Inc.
Pharmavite
Infinitus (china)
Mission Pharmacal Company
Oyster Shell
Allena Pharmaceuticals, Inc.
Amway Corp.
Celebrate Vitamins
Entring, Llc
Nature’s Bounty
Oxthera
Renew Life Formulas, Inc.
Synlogic
Tiens
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Secondary Hyperoxaluria Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 OTT Medicine
1.2.3 Prescription Medicine
1.3 Market by Application
1.3.1 Global Secondary Hyperoxaluria Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals Pharmacy
1.3.3 Online Pharmacy
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Secondary Hyperoxaluria Drug Market Perspective (2017-2028)
2.2 Secondary Hyperoxaluria Drug Growth Trends by Region
2.2.1 Secondary Hyperoxaluria Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Secondary Hyperoxaluria Drug Historic Market Size by Region (2017-2022)
2.2.3 Secondary Hyperoxaluria Drug Forecasted Market Size by Region (2023-2028)
2.3 Secondary Hyperoxaluria Drug Market Dynamics
2.3.1 Secondary Hyperoxaluria Drug Industry Trends
2.3.2 Secondary Hyperoxaluria Drug Market Drivers
2.3.3 Secondary Hyperoxaluria Drug Market Challenges
2.3.4 Secondary Hyperoxaluria Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Secondary Hyperoxaluria Drug Players by Revenue
3.1.1 Global Top Secondary Hyperoxaluria Drug Players by Revenue (2017-2022)
3.1.2 Global Secondary Hyperoxaluria Drug Revenue Market Share by Players (2017-2022)
3.2 Global Secondary Hyperoxaluria Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Secondary Hyperoxaluria Drug Revenue
3.4 Global Secondary Hyperoxaluria Drug Market Concentration Ratio
3.4.1 Global Secondary Hyperoxaluria Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Secondary Hyperoxaluria Drug Revenue in 2021
3.5 Secondary Hyperoxaluria Drug Key Players Head office and Area Served
3.6 Key Players Secondary Hyperoxaluria Drug Product Solution and Service
3.7 Date of Enter into Secondary Hyperoxaluria Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Secondary Hyperoxaluria Drug Breakdown Data by Type
4.1 Global Secondary Hyperoxaluria Drug Historic Market Size by Type (2017-2022)
4.2 Global Secondary Hyperoxaluria Drug Forecasted Market Size by Type (2023-2028)
5 Secondary Hyperoxaluria Drug Breakdown Data by Application
5.1 Global Secondary Hyperoxaluria Drug Historic Market Size by Application (2017-2022)
5.2 Global Secondary Hyperoxaluria Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Secondary Hyperoxaluria Drug Market Size (2017-2028)
6.2 North America Secondary Hyperoxaluria Drug Market Size by Type
6.2.1 North America Secondary Hyperoxaluria Drug Market Size by Type (2017-2022)
6.2.2 North America Secondary Hyperoxaluria Drug Market Size by Type (2023-2028)
6.2.3 North America Secondary Hyperoxaluria Drug Market Share by Type (2017-2028)
6.3 North America Secondary Hyperoxaluria Drug Market Size by Application
6.3.1 North America Secondary Hyperoxaluria Drug Market Size by Application (2017-2022)
6.3.2 North America Secondary Hyperoxaluria Drug Market Size by Application (2023-2028)
6.3.3 North America Secondary Hyperoxaluria Drug Market Share by Application (2017-2028)
6.4 North America Secondary Hyperoxaluria Drug Market Size by Country
6.4.1 North America Secondary Hyperoxaluria Drug Market Size by Country (2017-2022)
6.4.2 North America Secondary Hyperoxaluria Drug Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Secondary Hyperoxaluria Drug Market Size (2017-2028)
7.2 Europe Secondary Hyperoxaluria Drug Market Size by Type
7.2.1 Europe Secondary Hyperoxaluria Drug Market Size by Type (2017-2022)
7.2.2 Europe Secondary Hyperoxaluria Drug Market Size by Type (2023-2028)
7.2.3 Europe Secondary Hyperoxaluria Drug Market Share by Type (2017-2028)
7.3 Europe Secondary Hyperoxaluria Drug Market Size by Application
7.3.1 Europe Secondary Hyperoxaluria Drug Market Size by Application (2017-2022)
7.3.2 Europe Secondary Hyperoxaluria Drug Market Size by Application (2023-2028)
7.3.3 Europe Secondary Hyperoxaluria Drug Market Share by Application (2017-2028)
7.4 Europe Secondary Hyperoxaluria Drug Market Size by Country
7.4.1 Europe Secondary Hyperoxaluria Drug Market Size by Country (2017-2022)
7.4.2 Europe Secondary Hyperoxaluria Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Secondary Hyperoxaluria Drug Market Size (2017-2028)
8.2 Asia-Pacific Secondary Hyperoxaluria Drug Market Size by Type
8.2.1 Asia-Pacific Secondary Hyperoxaluria Drug Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Secondary Hyperoxaluria Drug Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Secondary Hyperoxaluria Drug Market Share by Type (2017-2028)
8.3 Asia-Pacific Secondary Hyperoxaluria Drug Market Size by Application
8.3.1 Asia-Pacific Secondary Hyperoxaluria Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Secondary Hyperoxaluria Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Secondary Hyperoxaluria Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific Secondary Hyperoxaluria Drug Market Size by Region
8.4.1 Asia-Pacific Secondary Hyperoxaluria Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Secondary Hyperoxaluria Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Secondary Hyperoxaluria Drug Market Size (2017-2028)
9.2 Latin America Secondary Hyperoxaluria Drug Market Size by Type
9.2.1 Latin America Secondary Hyperoxaluria Drug Market Size by Type (2017-2022)
9.2.2 Latin America Secondary Hyperoxaluria Drug Market Size by Type (2023-2028)
9.2.3 Latin America Secondary Hyperoxaluria Drug Market Share by Type (2017-2028)
9.3 Latin America Secondary Hyperoxaluria Drug Market Size by Application
9.3.1 Latin America Secondary Hyperoxaluria Drug Market Size by Application (2017-2022)
9.3.2 Latin America Secondary Hyperoxaluria Drug Market Size by Application (2023-2028)
9.3.3 Latin America Secondary Hyperoxaluria Drug Market Share by Application (2017-2028)
9.4 Latin America Secondary Hyperoxaluria Drug Market Size by Country
9.4.1 Latin America Secondary Hyperoxaluria Drug Market Size by Country (2017-2022)
9.4.2 Latin America Secondary Hyperoxaluria Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Secondary Hyperoxaluria Drug Market Size (2017-2028)
10.2 Middle East & Africa Secondary Hyperoxaluria Drug Market Size by Type
10.2.1 Middle East & Africa Secondary Hyperoxaluria Drug Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Secondary Hyperoxaluria Drug Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Secondary Hyperoxaluria Drug Market Share by Type (2017-2028)
10.3 Middle East & Africa Secondary Hyperoxaluria Drug Market Size by Application
10.3.1 Middle East & Africa Secondary Hyperoxaluria Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Secondary Hyperoxaluria Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Secondary Hyperoxaluria Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa Secondary Hyperoxaluria Drug Market Size by Country
10.4.1 Middle East & Africa Secondary Hyperoxaluria Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Secondary Hyperoxaluria Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Nestle
11.1.1 Nestle Company Details
11.1.2 Nestle Business Overview
11.1.3 Nestle Secondary Hyperoxaluria Drug Introduction
11.1.4 Nestle Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.1.5 Nestle Recent Developments
11.2 Glaxosmithkline Plc
11.2.1 Glaxosmithkline Plc Company Details
11.2.2 Glaxosmithkline Plc Business Overview
11.2.3 Glaxosmithkline Plc Secondary Hyperoxaluria Drug Introduction
11.2.4 Glaxosmithkline Plc Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.2.5 Glaxosmithkline Plc Recent Developments
11.3 Bayer Ag
11.3.1 Bayer Ag Company Details
11.3.2 Bayer Ag Business Overview
11.3.3 Bayer Ag Secondary Hyperoxaluria Drug Introduction
11.3.4 Bayer Ag Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.3.5 Bayer Ag Recent Developments
11.4 Now Foods
11.4.1 Now Foods Company Details
11.4.2 Now Foods Business Overview
11.4.3 Now Foods Secondary Hyperoxaluria Drug Introduction
11.4.4 Now Foods Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.4.5 Now Foods Recent Developments
11.5 Solgar Inc.
11.5.1 Solgar Inc. Company Details
11.5.2 Solgar Inc. Business Overview
11.5.3 Solgar Inc. Secondary Hyperoxaluria Drug Introduction
11.5.4 Solgar Inc. Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.5.5 Solgar Inc. Recent Developments
11.6 Pharmavite
11.6.1 Pharmavite Company Details
11.6.2 Pharmavite Business Overview
11.6.3 Pharmavite Secondary Hyperoxaluria Drug Introduction
11.6.4 Pharmavite Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.6.5 Pharmavite Recent Developments
11.7 Infinitus (china)
11.7.1 Infinitus (china) Company Details
11.7.2 Infinitus (china) Business Overview
11.7.3 Infinitus (china) Secondary Hyperoxaluria Drug Introduction
11.7.4 Infinitus (china) Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.7.5 Infinitus (china) Recent Developments
11.8 Mission Pharmacal Company
11.8.1 Mission Pharmacal Company Company Details
11.8.2 Mission Pharmacal Company Business Overview
11.8.3 Mission Pharmacal Company Secondary Hyperoxaluria Drug Introduction
11.8.4 Mission Pharmacal Company Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.8.5 Mission Pharmacal Company Recent Developments
11.9 Oyster Shell
11.9.1 Oyster Shell Company Details
11.9.2 Oyster Shell Business Overview
11.9.3 Oyster Shell Secondary Hyperoxaluria Drug Introduction
11.9.4 Oyster Shell Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.9.5 Oyster Shell Recent Developments
11.10 Allena Pharmaceuticals, Inc.
11.10.1 Allena Pharmaceuticals, Inc. Company Details
11.10.2 Allena Pharmaceuticals, Inc. Business Overview
11.10.3 Allena Pharmaceuticals, Inc. Secondary Hyperoxaluria Drug Introduction
11.10.4 Allena Pharmaceuticals, Inc. Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.10.5 Allena Pharmaceuticals, Inc. Recent Developments
11.11 Amway Corp.
11.11.1 Amway Corp. Company Details
11.11.2 Amway Corp. Business Overview
11.11.3 Amway Corp. Secondary Hyperoxaluria Drug Introduction
11.11.4 Amway Corp. Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.11.5 Amway Corp. Recent Developments
11.12 Celebrate Vitamins
11.12.1 Celebrate Vitamins Company Details
11.12.2 Celebrate Vitamins Business Overview
11.12.3 Celebrate Vitamins Secondary Hyperoxaluria Drug Introduction
11.12.4 Celebrate Vitamins Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.12.5 Celebrate Vitamins Recent Developments
11.13 Entring, Llc
11.13.1 Entring, Llc Company Details
11.13.2 Entring, Llc Business Overview
11.13.3 Entring, Llc Secondary Hyperoxaluria Drug Introduction
11.13.4 Entring, Llc Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.13.5 Entring, Llc Recent Developments
11.14 Nature’s Bounty
11.14.1 Nature’s Bounty Company Details
11.14.2 Nature’s Bounty Business Overview
11.14.3 Nature’s Bounty Secondary Hyperoxaluria Drug Introduction
11.14.4 Nature’s Bounty Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.14.5 Nature’s Bounty Recent Developments
11.15 Oxthera
11.15.1 Oxthera Company Details
11.15.2 Oxthera Business Overview
11.15.3 Oxthera Secondary Hyperoxaluria Drug Introduction
11.15.4 Oxthera Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.15.5 Oxthera Recent Developments
11.16 Renew Life Formulas, Inc.
11.16.1 Renew Life Formulas, Inc. Company Details
11.16.2 Renew Life Formulas, Inc. Business Overview
11.16.3 Renew Life Formulas, Inc. Secondary Hyperoxaluria Drug Introduction
11.16.4 Renew Life Formulas, Inc. Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.16.5 Renew Life Formulas, Inc. Recent Developments
11.17 Synlogic
11.17.1 Synlogic Company Details
11.17.2 Synlogic Business Overview
11.17.3 Synlogic Secondary Hyperoxaluria Drug Introduction
11.17.4 Synlogic Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.17.5 Synlogic Recent Developments
11.18 Tiens
11.18.1 Tiens Company Details
11.18.2 Tiens Business Overview
11.18.3 Tiens Secondary Hyperoxaluria Drug Introduction
11.18.4 Tiens Revenue in Secondary Hyperoxaluria Drug Business (2017-2022)
11.18.5 Tiens Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の二次高シュウ酸尿症薬市場インサイト及び予測(OTT薬、処方薬)(Global Secondary Hyperoxaluria Drug Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。